por John R. Fischer
, Senior Reporter | October 28, 2020
Researchers at the 2020 ASTRO virtual Annual Meeting are touting a new study that demonstrates the ability of PSMA PET/CT to distinguish between localized and metastatic cases of high-risk prostate cancer.
Staging of the disease is currently done with the use of a CT scan, usually of the abdomen and pelvis, and a technetium bone scan. The authors say the findings of their post hoc analysis show the effective role that PSMA PET/CT plays in the management of high-risk prostate cancer. The title of the study is Impact of 68Ga-PSMA-11 PET/CT on Initial Staging of High-Risk Prostate Cancer Patients: Post-Hoc Analysis of a Prospective Single Center Experience on the staging impact of PSMA PET/CT in men with NCCN high-risk prostate cancer
“Conventional imaging for initial staging of prostate cancer (PCa) lacks sensitivity and underestimates disease burden,” said the authors in their study. “Prostate-specific membrane antigen PET/CT (PSMA PET) is an emerging imaging modality shown to have improved sensitivity over conventional imaging in the setting of biochemical recurrence.”
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
The study evaluated 249 patients with NCCN high/very high risk PCa who underwent PSMA PET imaging in a prospective trial between December 2016 and January 2020. PSMA PET upstaged 22.9% of patients, with 18.9% who were diagnosed with iN0 disease by CT or MR found to have N1 disease, and 10.6% given an M0 disease status by CT or bone scan now given an M1 disease status. Meanwhile, 7.4% received a new M1a disease and 5.3% were found to have M1b/M1c disease. In addition, PSMA PET detected ECE (the local spread of cancer beyond the prostate), seminal vesicle invasion or invasion of surrounding structures in 8.1% of patients ranked as T2 on prior MR imaging.
Those with a grade group of five or percentage of positive biopsy cores (PPC)≥50% were more likely to have regional nodal upstage and any upstage in general, while patients with GG 5 together with ≥50% PPC were predicted to have M stage upstage. cT and iPSA were not associated with upstaging.
While increasing in availability worldwide due to its higher sensitivity and specificity over conventional imaging, PSMA PET/CT is still limited in use, including in the U.S. where the FDA has not yet approved the agent.
Overall, PSMA PET/CT identified 19.7% of patients with regional PET positive nodal disease and 9.4% with metastatic disease on PET/CT. While not uniformly biopsy-proven areas for metastatic disease, it is possible based on prior research that 85%-98% of lesions found in these areas are likely to be prostate cancer, according to Dr. Daniel Spratt, a radiation oncologist at the University of Michigan who saw the presentation. He adds that the findings show that GG 5 (Gleason Score of 9-10) and >50% of biopsy cores involved with cancer predicted for non-localized prostate cancer.
“Based on clinical trials led out of UCLA, UCSF and other centers, I am hopeful that these molecular imaging modalities can soon be added to our toolbox to better personalize our treatments,” wrote Spratt in an ASTRO op-ed
The findings were published in the International Journal of Radiation Oncology · Biology · Physics